Navigation Links
PDI Reports 2014 Second Quarter Financial Results
Date:8/13/2014

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the second quarter ended June 30, 2014. Summary financial and operational accomplishments include:

  • Revenue of $31.6 million for the second quarter of 2014
  • Adjusted EBITDA (a non-GAAP financial measure) of $(1.5) million for the second quarter of 2014
  • On August 13, 2014, PDI acquired Asuragen, Inc.'s miRInform Thyroid and miRInform Pancreas cancer test assets
  • Subsequent to the second quarter, Heiner Dreismann, Ph.D., a highly experienced molecular diagnostics executive and former President and CEO of Roche Molecular Systems, joined PDI's board of directors
  •  

     Condensed Summary Statements of Continuing Operations (Unaudited)($'s in thousands, expect per share data)2nd Quarter EndedSix Months EndedJune 30,*June 30,*2014201320142013Revenue, net$
    31.6
    $
    37.2
    $
    4.4
    $
    80.2
    Gross profit4.86.89.915.3Operating expenses:Compensation expense3.94.97.49.1Other SG&A3.52.86.54.8Total operating expenses7.37.713.913.9Operating (loss) income $
    (2.5)
    $
    (0.8)
    $
    (4.0)
    $
    .4
    Provision for income tax0.10.10.10.1(Loss) income from continuing operations$
    (2.6)
    $
    (0.9)
    $
    (4.2)
    $
    .2
    Diluted (loss) income per share from continuing operations$
    (0.17)
    $
    (0.06)
    $
    (0.28)
    $
    .08
      *Unaudited 

    CEO Comments"We are extremely excited to announce the agreement to acquire specific diagnostic assets from Asuragen, Inc. The transaction is the first step for our Interpace Diagnostic subsidiary in expanding into higher growth, higher margin markets and starts to establish Interpace as a commercially focused molecular diagnostic subsidiary," said Nancy Lurker, CEO.

    "The transaction includes two oncology assays, miRInform Thyroid and miRInform Pancreas, associated intellectual property, a large biobank with over 5,000 patient tissue samples, as well as, additional thyroid tests in development."

    "In addition, Heiner Dreismann, Ph.D., has joined our board of directors and brings with him nearly 30 years of experience in the diagnostic industry and extensive background in molecular diagnostics including his former tenure as President and CEO of Roche Molecular Systems. We look forward to his invaluable insight as we continue to evolve as a company."

    "In terms of second quarter results, our revenue of $32 million were in line with our expectations and continues to reflect the soft RFP volume we experienced in our Sales Services business. Gross margins of 15%, while down compared to last year, are in line with current industry norms. Our adjusted EBITDA loss of $1.5 million in the quarter was primarily driven by spending on our key strategic initiatives and lower gross profit," said Nancy Lurker, CEO.

    Ms. Lurker continued, "As for our outlook for the remainder of the year, we continue to expect revenue in our core business to be down in the third quarter and for the full year compared to 2013. We still anticipate an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. Given today's Asuragen transaction, we now see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets."

    Second Quarter Business Review Revenue- For the second quarter of 2014, revenue of $31.6 million was $5.7 million or 15% lower than the second quarter of 2013 driven by the natural expiration or reduction of contracts being executed in 2014 exceeding new contracts entered into in the company's Sales Services segment.

  • Sales Services revenue of $28.1 million was $4.2 million lower than the second quarter of 2013. New contract wins from the softer RFP volume experienced in the latter half of 2013 was not sufficient to offset the natural expiration or reduction of certain contracts.
  • Marketing Services revenue of $0.6 million was $1.0 million lower than the second quarter of 2013 due to fewer contract signings by Group DCA.
  • Product Commercialization Services revenue of $2.9 million was $0.4 million lower than the second quarter of 2013.
  • Gross Profit- For the second quarter of 2014, gross profit of $4.8 million was $2.1 million lower than the second quarter of 2013 and, as anticipated, the overall gross profit percentage decreased to 15% in 2014 from 18% in 2013.

  • Sales Services gross profit of $4.8 million was $0.5 million lower than the second quarter of 2013 due primarily to lower revenue and previously disclosed competitive pricing pressures.
  • Marketing Services gross profit for the second quarter of 2014 was a negative $0.5 million due to the decrease in revenue and increased costs associated with the launch of our new product, PD One™.
  • Product Commercialization Services gross profit of $0.6 million was $0.4 million lower compared to the second quarter of 2013 primarily due to expenses related to one of our collaboration agreements for molecular diagnostic tests.
  • Total Operating Expenses- Total operating expenses for the second quarter of 2014 were $7.3 million as compared to $7.7 million for the same period in 2013. Included in second quarter 2014 expenses are $0.7 million of investment costs related to our molecular diagnostics strategic initiative. Excluding these costs, total operating expenses for the second quarter of 2014 were $6.6 million; $1.1 million lower than 2013 operating expenses.

    Operating Income/Loss- The operating loss for the second quarter of 2014 was $2.5 million, compared to $0.8 million for the same period in 2013.  The 2014 operating loss was primarily the result of the anticipated lower revenue and margins as well as the company's investment in strategic initiatives.

    Liquidity and Cash Flow- Adjusted EBITDA (a non-GAAP measure defined in the release) for the second quarter of 2014 was $(1.5) million compared to $0.2 million in the second quarter of 2013. Cash and cash equivalents at the end of the second quarter were $35.6 million, down $10.0 million from December 31, 2013 due primarily to increases in working capital requirements, timing of certain payments from customers and investments in our strategic initiatives. Factoring in the Asuragen acquisition and anticipated additional spending in Interpace Diagnostics, the company estimates year end 2014 cash of $22 - $25 million.

    As of June 30, 2014, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.

    Non-GAAP Financial MeasuresIn addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, PDI has provided a certain non-GAAP financial measure to help evaluate the results of its performance. The company believes that this non-GAAP financial measure, when presented in conjunction with comparable GAAP financial measure, is useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.

    In this document, the company discusses Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as operating income or loss, plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

     Adjusted EBITDA (Unaudited)($ in thousands)2nd Quarter EndedSix Months EndedJune 30,June 30,2014201320142013Operating (loss) income 

    $
    (2,523)
    $
    (847)
    $
    (4,020)
    $
    ,406
    Depreciation and amortization

    380289837577Stock compensation6687221,3581,073Adjusted EBITDA$
    (1,475)
    $
    4
    $
    (1,825)
    $
    3,056
     

    Conference CallAs previously announced, PDI will hold a conference call Thursday, August 14, 2014 to discuss financial and operational results of the second quarter ended June 30, 2014.  Details as follows:

    Time: 8:30 AM (ET)
    Dial-in numbers: (855) 592-8761 (U.S. and Canada) or (724) 924-4975
    Conference ID#: 27904432

    Live webcast: www.pdi-inc.com, under "Investor Relations"

    The teleconference replay will be available three hours after completion through September 13, 2014 at (855) 859-2056 (U.S. and Canada) or (404) 537-3406. The replay pass code is 27904432. The archived web cast will be available for one year.

    About PDI, Inc.PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. PDI's Interpace Diagnostics division is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company's Contract Sales business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.

    For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.

    Forward-Looking StatementsThis press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

     PDI, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)(in thousands, except per share data)Three Months EndedSix Months EndedJune 30,June 30,2014201320142013Revenue, net

    $
    31,578
    $
    37,245
    $
    4,356
    $
    80,168
    Cost of services

    26,78730,39654,45664,846Gross profit

    4,7916,8499,90015,322Compensation expense

    3,8624,9147,4039,069Other selling, general and administrative expenses

    3,4522,7826,5174,847Total operating expenses

    7,3147,69613,92013,916Operating (loss) income 

    (2,523)(847)(4,020)1,406Other expense, net

    (13)(24)(30)(34)(Loss) income from continuing operations beforeincome tax

    (2,536)(871)(4,050)1,372Provision for income tax

    6564131128(Loss) income from continuing operations

    (2,601)(935)(4,181)1,244(Loss) income  from discontinued operations, net of tax

    (57)52(89)(2)Net (loss) income 

    $
    (2,658)
    $
    (883)
    $
    (4,270)
    $
    ,242
    Basic (loss) income per share of common stock:From continuing operations

    $
    (0.17)
    $
    (0.06)
    $
    (0.28)
    $
    .08
    From discontinued operations

    (0.01)-(0.01)-Net (loss) income per basic share of common stock

    $
    (0.18)
    $
    (0.06)
    $
    (0.29)
    $
    .08
    Diluted (loss) income per share of common stock:From continuing operations

    $
    (0.17)
    $
    (0.06)
    $
    (0.28)
    $
    .08
    From discontinued operations

    (0.01)-(0.01)-Net (loss) income per diluted share of common stock

    $
    (0.18)
    $
    (0.06)
    $
    (0.29)
    $
    .08
    Weighted average number of common shares andcommon share equivalents outstanding:Basic

    14,91014,71314,86014,691Diluted

    14,91014,71314,86015,154 Segment Data (Unaudited)($ in thousands)SalesMarketingPCServicesServicesServices*ConsolidatedThree months ended June 30, 2014:Revenue, net

    $
    28,067
    $
    4
    $
    2,897
    $
    31,578
    Gross profit (loss)

    $
    4,765
    $
    (526)
    $
    552
    $
    4,791
    Gross profit %

    17.0%-85.7%19.1%15.2%Three months ended June 30, 2013:Revenue, net

    $
    32,294
    $
    ,644
    $
    3,307
    $
    37,245
    Gross profit

    $
    5,252
    $
    38
    $
    959
    $
    ,849
    Gross profit %

    16.3%38.8%29.0%18.4%SalesMarketingPCServicesServicesServices*ConsolidatedSix months ended June 30, 2014:Revenue, net

    $
    56,862
    $
    ,617
    $
    5,877
    $
    4,356
    Gross profit (loss)

    $
    9,508
    $
    (694)
    $
    ,086
    $
    9,900
    Gross profit %

    16.7%-42.9%18.5%15.4%Six months ended June 30, 2013:Revenue, net

    $
    70,519
    $
    3,185
    $
    ,464
    $
    80,168
    Gross profit

    $
    2,571
    $
    ,022
    $
    ,729
    $
    5,322
    Gross profit %

    17.8%32.1%26.7%19.1%* Product Commercialization (PC) Services 

     Selected Balance Sheet Data (Unaudited)($ in thousands) June 30,  December 31, 20142013Cash and cash equivalents

    $
    35,621
    $
    45,639
    Total current assets

    $
    53,176
    $
    2,709
    Total current liabilities

    25,62131,400Working capital

    $
    27,555
    $
    31,309
    Total assets

    $
    59,459
    $
    9,064
    Total liabilities

    $
    30,107
    $
    36,585
    Total stockholders' equity

    $
    29,352
    $
    32,479
    Selected Cash Flow Data (Unaudited)($ in thousands)June 30,20142013Net (loss) income

    $
    (4,270)
    $
    ,242
    Non-cash items:Depreciation and amortization

    837577Stock-based compensation

    1,3581,073Other

    7171Net change in assets and liabilities

    (6,284)(3,537)Net cash used in operations

    $
    (8,288)
    $
    (574)
    Change in cash and cash equivalents

    $
    (10,018)
    $
    (1,760)
    Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO


    '/>"/>
    SOURCE PDI, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
    2. Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
    3. Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
    4. Aratana Therapeutics Reports Second Quarter 2014 Results
    5. Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014
    6. Halozyme Reports Second Quarter 2014 Financial Results
    7. Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
    8. AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
    9. Omeros Corporation Reports Second Quarter 2014 Financial Results
    10. Darling Ingredients Inc. Reports Commencement Of Exchange Offer For 5.375% Senior Notes Due 2022
    11. Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
    (Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
    (Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
    (Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
    (Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
    Breaking Medicine News(10 mins):